Skip to main content
SpringerLink
Log in

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

During the last 10 years, three European phase II studies were performed to investigate the treatment of elderly patients with myelodysplastic syndrome (MDS) with low-dose 5-aza-2′-deoxycytidine (decitabine, DAC). All these European trial data were reviewed on the basis of the International Prognostic Scoring System (IPSS) risk criteria and the response criteria as recently published by an international working group. To investigate the results in a larger cohort of patients and to determine risk factors, all data were pooled with some observations from the PCH 95-06 US phase II study. The response rate in the 177 patients evaluated (median age 70 years) was 49%. The median response duration was 36 weeks, and the median survival was 15 months. Analysis of the data according to sex, age, French–American–British classification, percentage of blasts in the bone marrow, IPSS risk group, lactate dehydrogenase and cytogenetics did not reveal any factor predictive of response. Overall, 69% of patients benefited, including those with stable disease during therapy. Response duration was significantly shorter with increasing risk (according to the IPSS classification). Haemoglobin level and neutrophil count showed an inverse correlation to the IPSS classification. Univariate analysis showed a significantly inferior survival for elderly patients (>75 years of age) and for those with high levels of serum lactate dehydrogenase (LDH) (more than two times the normal values). Patients with high-risk cytogenetic abnormalities according to the IPSS risk criteria showed better overall survival than those with intermediate-risk abnormalities. When analysed according to the IPSS risk classification, high-risk patients had worse survival prospects following decitabine therapy than those with intermediate risk; however, compared to the originally reported IPPS outcomes for high-risk patients, they probably showed better survival. During the treatment period, 18% of the patients progressed towards acute leukaemia. Decitabine showed a rather low toxicity profile in this elderly patient group. In conclusion, low-dose decitabine is an active drug for the treatment of MDS patients, even for those older than 75 years with bad prognostic characteristics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Aoki E, Uchida T, Ohashi H, Murase T, Ichikawa A, Yamao K, Hotta T, Kinoshita T, Saito H, Murate T (2000) Methylation status of the p15ink4b gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndrome. Leukemia 14:586–593

    Article  PubMed  CAS  Google Scholar 

  2. Bennet JM, Catovskty D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 74:395–408

    Google Scholar 

  3. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte T, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg P (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671–3674

    PubMed  CAS  Google Scholar 

  4. Cheson BD, Jaspern DM, Simon R, Friedman MA (1986) A critical appraisal of low dose cytosine arabinoside in patients with acute non lymphocytic leukaemia and myelodysplastic syndrome. J Clin Oncol 4:1857–1864

    PubMed  CAS  Google Scholar 

  5. Christman JK (2002) 5-azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21:5483–5495

    Article  PubMed  CAS  Google Scholar 

  6. Clark SJ, Melki J (2002) DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 21:5380–5387

    Article  PubMed  CAS  Google Scholar 

  7. Daskalakis M, Nguyen TT, Nguyen C, Goldberg P, Ko G, Wijermaqns P, Jones PA, Lübbert M (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957–2964

    Article  PubMed  CAS  Google Scholar 

  8. Erratum (1998) Blood 91:1100

    Google Scholar 

  9. Greenberg P, Cox C, Le Bau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashi K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088

    PubMed  CAS  Google Scholar 

  10. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R, FDA (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11:3604–3608

    Article  PubMed  CAS  Google Scholar 

  11. Kornblith AB, Herndon JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B Study. J Clin Oncol 15:2441–2452

    Article  CAS  Google Scholar 

  12. Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM (2004) Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22:1287–1292

    Article  PubMed  CAS  Google Scholar 

  13. Lübbert M, Wijermans P, Kunzman R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2001) Cytogenetic responses in high risk myelodysplastic syndrome following low dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114:1–11

    Article  Google Scholar 

  14. Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DR, Cassileth PA, O'Connell MJ, Kyungmann K (1992) The evaluation of low dose cytarabine in the treatment of myelodysplastic syndrome: a phase III intergroup study. Ann Hematol 65:162–168

    Article  PubMed  CAS  Google Scholar 

  15. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M, Fenaux P (1998) Methylation of the p15ink4b gene in myelodysplastic syndrome is frequent and acquired during disease progression. Blood 91:2985–2990

    PubMed  CAS  Google Scholar 

  16. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JM (2002) Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20:2429–2440

    Article  PubMed  CAS  Google Scholar 

  17. Wijermans PW, Krulder JWM, Huijgens PC, Neve P (1997) Continuous infusion of low dose 5-aza-2′-deoxycytidine in elderly patients with high risk myelodysplastic syndrome. Leukemia 11:1–5

    Article  PubMed  CAS  Google Scholar 

  18. Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2002) Low dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18:956–962

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Leyenburg Hospital, Leyweg 245, 2545 CH, The Hague, The Netherlands

    P. W. Wijermans

  2. Department of Medicine, Division of Hematology/Oncology, University of Freiburg Medical Centre, Freiburg, Germany

    M. Lübbert

  3. Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium

    G. Verhoef

  4. Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    V. Klimek

  5. Department of Hematology, ACL Mont-Godinne, Mont Godinne, Belgium

    A. Bosly

Authors
  1. P. W. Wijermans
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Lübbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Verhoef
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Klimek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Bosly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. W. Wijermans.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wijermans, P.W., Lübbert, M., Verhoef, G. et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 84 (Suppl 1), 9–17 (2005). https://doi.org/10.1007/s00277-005-0012-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-0012-1

Keywords

Search

Navigation